Page 181 - Drug Class Review
P. 181
Drug Effectiveness Review Project
Alzheimer classification: Mild to moderate
Groups similar at baseline: Yes
donepezil 5 mg placebo donepezil 10 mg 74.0 73.4 73.8 61 61 69 96% 96% 95% 4% 1% 4% 0% 3% 1% 19.8 19.35 19.39 Primary Outcome Measures: ADAS-Cog; CIBIC-plus Secondary Outcome Measures: MMSE; CDR-SB; unspecified 7-item QOL scale Timing of assessments: Baseline and three week intervals throughout trial Health Outcome Measures: Mean QOL score was significantly better than placebo for DON 10 mg/d (P = 0.02) but not 5 mg/d Intermediate Outcome Measures: Mean change in ADAS-Cog: -2.1 for the 5 mg/d DON group (95% CI: -3.59
• • • • •
Final Report Update 1 Authors: Rogers et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Mean baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
